The Fontan Procedure for Pediatric Tricuspid Atresia 

  • Author: Prema Ramaswamy, MD; Chief Editor: John Kupferschmid, MD   more...
 
Updated: Aug 4, 2011
 

Background

The malformation of tricuspid atresia consists of a complete agenesis of the tricuspid valve with an absence of a direct communication between the right atrium and right ventricle. Tricuspid atresia is the third most common form of cyanotic congenital heart disease. It is also the most common cause of cyanosis with left ventricular hypertrophy.

The natural history of this condition is such that, without surgical intervention, only one third of patients survive to age 1 year and only 10% live to age 10 years.[1] The Fontan procedure, which was first performed in 1968 and then described in 1971, has changed the natural history dramatically and allowed survival into the third and fourth decades of life.[2]

Next

History of the Procedure

The Fontan operation is named for Fontan, who was the first to describe an operation for patients with tricuspid atresia that could result in separate systemic and pulmonary circulations despite the absence of a ventricle, in this case, the right ventricle. Until that description, a pumping chamber was assumed to be essential to move the blood through the lungs. Although the Glenn operation, which involves the end-to-end anastomosis of the superior vena cava (SVC) to the right pulmonary artery, was described in 1958, it was primarily used as palliative surgery.[3] It was used to augment pulmonary blood flow as an alternate to the Blalock-Taussig shunt procedure. Patients remained cyanotic because the return from the inferior vena cava (IVC) still entered the heart and mixed with the pulmonary venous return. Moreover, the left ventricle continued to have the additional volume load of the IVC return.

Fontan was the first to completely bypass the right heart in a human subject and to channel both the IVC and SVC blood to the pulmonary arteries. He unsuccessfully attempted to bypass the right heart in healthy dogs. However, he reasoned that it may work in patients with tricuspid atresia because the right atrium is thicker and more muscular in humans than in canines and hence better able to perform a contractile function. He also believed that valved conduits were essential to prevent the blood from going in the opposite direction (ie, into the IVC). Therefore, he incorporated one valved homograft between the IVC and the right atrium and another valved homograft between the right atrium and the left pulmonary artery.

The final operation consisted of the classic Glenn SVC–to–right pulmonary artery operation as well as the right atrium–to–left pulmonary artery connection with the 2 homografts, as described. He published his results from the first three patients in 1971.[2]

Kreutzer et al (1973) offered a modification almost immediately.[4] They described a connection between the right atrial appendage and the main pulmonary artery accomplished by means of a pulmonary homograft or the patient's own pulmonary annulus but without a valved homograft at the IVC–right atrial junction. In this situation, the continuity of the pulmonary arteries is maintained.

Since these original articles were published, several other modifications have been described. These have greatly reduced the mortality and morbidity previously associated with tricuspid atresia. In addition, the Fontan-Kreutzer operation is applicable to all cardiac conditions where only a single functional ventricle is present.

Previous
Next

Problem

The basic problem arises from the absent connection between the right atrium and pulmonary artery due to the absent tricuspid valve. Hence, the only egress to the blood entering the right atrium is into the left atrium through an interatrial communication. This combined venous return then enters the left ventricle and is pumped out into the aorta. Some of this blood finds its way into the pulmonary artery through a ventricular septal defect or a patent ductus arteriosus.

Previous
Next

Epidemiology

Frequency

The true prevalence is unknown, but a rate reported in clinical studies was approximately 1.5%. An autopsy series revealed a prevalence of approximately 3%.[5] The calculated incidence is 1 case per every 10,000 live births. No sex dominance is known, and girls and boys are almost equally affected.

Previous
Next

Etiology

The cause of tricuspid atresia is unknown. Although specific genetic causes of the malformation have not been determined in humans, data indicate that the FOG2 gene may be involved in the process. Mice in which the FOG2 gene is knocked out are born with tricuspid atresia.[6] The significance of this finding and its applicability in humans has yet to be defined.

Previous
Next

Pathophysiology

Because of the absence of the tricuspid valve and the lack of continuity between the right atrium and the right ventricle, venous blood returning to the right atrium can exit only by means of an intra-atrial connection. Because this situation leads to an obligate right-to-left shunt at the level of the atria, saturation of the left atrial blood is diminished, and hypoxia and cyanosis result.

The classification is discussed below. However, in the most common type (type Ib), left atrial blood enters the left ventricle and is pumped out into the aorta. Some of this blood may reach the lungs through a small ventricular septal defect or through a patent ductus arteriosus if the ventricular septum is intact. In most cases of tricuspid atresia, pulmonary blood flow is restricted, leading to reduced pulmonary venous return and hence additional cyanosis. In this scenario, the single left ventricle can easily handle the added volumes of the systemic and the pulmonary venous return.

On the contrary, in patients with tricuspid atresia, a large ventricular septal defect, and no pulmonic stenosis (type IIc or rare cases of type Ic), pulmonary blood flow is excessive. This can manifest as congestive cardiac failure early and predispose the patient to the pulmonary vascular disease late. Because of the large amount of pulmonary venous return, cyanosis may be difficult to detect. Also, this excessive pulmonary venous return can pose a volume burden on the single ventricle and contribute to congestive cardiac failure.

Previous
Next

Presentation

Tricuspid atresia is usually detected in the neonatal period. Cyanosis is the most prominent feature, and this is due to the obligate intracardiac right to left shunt. However, the amount of pulmonary venous return modulates this sign. Cyanosis is most prominent in patients with restricted pulmonary blood flow (type Ib) and least noticeable in those with excessive pulmonary blood flow (types I and IIc). In the latter group, symptoms of congestive heart failure and pulmonary edema predominate. Examples are feeding and breathing difficulties, frequent respiratory infections, and growth failure. Clinical signs include tachypnea, tachycardia, and an enlarged liver.

Hypoxic-cyanotic spells may occur in infants with tricuspid atresia and diminished pulmonary blood flow, similar to those seen in tetralogy of Fallot. These episodes are potentially life-threatening and are indications for surgery.

Polycythemia is a consequence of the cyanosis and, as in other conditions with cyanosis, cerebrovascular accidents are a risk in infants with iron deficiency anemia. In older, nonsurgically treated children, brain abscesses may occur because the filtering function of the lungs is no longer operational in the presence of a right-to-left intracardiac shunt. These are uncommon at this time because children with tricuspid atresia undergo the Fontan procedure typically around age 2-4 years; this effectively separates the systemic and the pulmonary circulations.

The combination of cyanosis, polycythemia, and the artificial material used for modified Blalock-Taussig shunts predispose older patients receiving surgical palliation to bacterial endocarditis.

Previous
Next

Indications

The treatment for tricuspid atresia is predominantly surgical. Because one of the requirements for a Fontan procedure is low pulmonary vascular resistance, this operation cannot be performed in neonates. Hence, an interim palliative procedure may be needed depending on the amount of pulmonary blood flow. Most infants with tricuspid atresia have restrictive pulmonary blood flow. Therefore, after initial medical stabilization is achieved with intravenously administered prostaglandin 1 (PGE1), the first surgical intervention is palliative pulmonary-to-systemic anastomosis to increase pulmonary blood flow and to improve systemic oxygenation. These aims are achieved by using a modified Blalock-Taussig shunt, which is a small polytetrafluoroethylene (PTFE) graft to connect the subclavian artery and a pulmonary artery.

In those few patients with no pulmonary obstruction, a pulmonary artery band may initially be required to prevent the onset of pulmonary vascular disease.

In patients with a balanced circulation secondary to pulmonary obstruction that is not severe, no immediate intervention may be required at birth. However, they may undergo a bidirectional Glenn procedure after about age 3 months, by which time the pulmonary vascular resistance decreases to low levels. This procedure is essentially an anastomosis between the SVC and the pulmonary artery. One of the major advantages of this procedure is that it results in volume unloading of the left ventricle. Early volume unloading improves exercise capacity in preadolescents with the Fontan procedure.[7] Furthermore, this may serve as a first stage for subsequent surgery involving total cavopulmonary anastomosis (ie, modified Fontan procedure).

Choussat et al (1977) delineated selection criteria to define an ideal candidate for a Fontan procedure.[8] They described the 10 following criteria, which are occasionally and facetiously referred to as the 10 commandments for an ideal Fontan operation.

  • Age older than 4 years
  • Sinus rhythm
  • Normal systemic venous return
  • Normal right atrial volume
  • Mean pulmonary artery pressure less than 15 mm Hg
  • Pulmonary arteriolar resistance less than 4 Wood units/m2
  • Pulmonary artery–aorta ratio more than 0.75
  • Left ventricular ejection fraction more than 0.60
  • Competent mitral valve
  • Absence of pulmonary artery distortion

Due to the several modifications of the operation that have followed its initial description, the absence of most of the above criteria is regarded as only relative contraindications. Current absolute contraindications are a pulmonary vascular resistance above 4 Wood units/m2, severe hypoplasia of the pulmonary arteries, and severe diastolic dysfunction of the left ventricle.

Previous
Next

Relevant Anatomy

The morphology of the atretic tricuspid valve is most often muscular but is occasionally an imperforate membrane. In rare cases, it is Ebstenoid, or it has no connection between the tricuspid valve and the right ventricle. Systemic venous blood entering the right atrium can exit the atrium only through an interatrial communication. In 80% of patients, this interatrial communication is a stretched patent foramen ovale. In most of the remainder, it may be a secundum atrial septal defect.

The right ventricle is small and hypoplastic when no ventricular septal defect is present. In the presence of a ventricular septal defect, the right ventricle may be better developed than it is without the defect, but even then it is smaller than normal. The most common ventricular septal defect in tricuspid atresia is muscular, but it is occasionally perimembranous.

Almost 100 years ago in 1906, Kuhne proposed a classification scheme for tricuspid atresia based on the great artery orientation.[9] Tandon and Edwards reevaluated and redefined this scheme in 1974, and this is the classification in general use at this time.[10] As mentioned before, this system is primarily based on associated anomalies.

The relationship of the great artery defines the type, as follows: Type I involves normally related great arteries, type II is D-transposition of the great arteries, and type III is L-transposition of the great arteries. The subtypes a, b, and c depend on the degree of pulmonary obstruction and, to a lesser degree, the presence of a ventricular septal defect. Subtype a is pulmonary atresia, b is pulmonic stenosis, and c is no pulmonary obstruction.

Type Ib is the most common; this is tricuspid atresia with normally related great arteries, a small ventricular septal defect, and pulmonic stenosis. Type I accounts for 80% of all cases, and type III is the rarest and responsible for 3-7% of all cases.

About 60% of patients with transposition of the great arteries may have additional cardiovascular abnormalities.[11] A persistent left superior vena cava (SVC) is seen in 15% of patients. Patients with tricuspid atresia, transposition of the great arteries, and large pulmonary flow (type IIc) are most likely to also have a coarctation of the aorta, hypoplasia of the aortic arch, and a patent ductus arteriosus. This is in contrast to patients with tricuspid atresia and normally related great vessels, an intact ventricular septum, or a small ventricular septal defect (type Ia or Ib). These patients tend to have a small patent ductus arteriosus and a large ascending aorta and isthmus. Juxtaposition of the atrial appendages is reported in 40% of patients with tricuspid atresia and transposition of the great arteries.[12]

Previous
Next

Contraindications

The Fontan operation has only a few absolute contraindications at this time: pulmonary vascular resistance more than 4 Wood units/m2, severe hypoplasia of the pulmonary arteries, and severe diastolic dysfunction of the left ventricle.

The age at which a Fontan is performed has been steadily lowered, and several centers perform it at age 2 years or even younger in patients with good anatomy and physiology.[13] The advantage of performing a Fontan operation at an early age is improving oxygenation, which may enhance somatic growth and neurodevelopmental outcomes. It also reduces the volume load on the single ventricle.

Previous
Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Prema Ramaswamy, MD  Associate Professor of Clinical Pediatrics, State University of New York Downstate; Adjunct Assistant Clinical Professor of Pediatrics, St George's University School of Medicine; Co-Director of Pediatric Cardiology, Maimonides Medical Center, Lutheran Medical Center, and Coney Island Hospital

Prema Ramaswamy, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Cardiology

Disclosure: Nothing to disclose.

Coauthor(s)

Mary C Mancini, MD, PhD  Professor and Chief of Cardiothoracic Surgery, Department of Surgery, Louisiana State University School of Medicine in Shreveport

Mary C Mancini, MD, PhD is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, Society of Thoracic Surgeons, and Southern Surgical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Jonah Odim, MD, PhD, MBA  Senior Medical Officer, Transplantation Immunology Branch, Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Jonah Odim, MD, PhD, MBA is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physician Executives, American College of Surgeons, American Heart Association, American Society for Artificial Internal Organs, American Society of Transplant Surgeons, Association for Academic Surgery, Association for Surgical Education, Canadian Cardiovascular Society, International Society for Heart and Lung Transplantation, National Medical Association, New York Academy of Sciences, Royal College of Physicians and Surgeons of Canada, Society of Critical Care Medicine, and Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Samuel Weinstein, MD  Associate Professor, Albert Einstein College of Medicine; Director, Department of Pediatric Cardiothoracic Surgery, The Children's Hospital at Montefiore

Samuel Weinstein, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, American Medical Association, Ohio State Medical Association, and Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

John Kupferschmid, MD  Director of Congenital Heart Surgery, Department of Surgery, Methodist Children's Hospital at San Antonio

John Kupferschmid, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, Society of Thoracic Surgeons, and Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

References
  1. Keith JD, Rowe RD, Vlad P. Tricuspid Atresia. New York, NY: Macmillan; 1958.

  2. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. May 1971;26(3):240-8. [Medline].

  3. Glenn WW. Circulatory bypass of the right side of the heart. IV. Shunt between superiorvena cava and distal right pulmonary artery; report of clinical application. N Engl J Med. Jul 17 1958;259(3):117-20. [Medline].

  4. Kreutzer G, Galindez E, Bono H, et al. An operation for the correction of tricuspid atresia. J Thorac Cardiovasc Surg. Oct 1973;66(4):613-21. [Medline].

  5. Nadas AS, Fyler DC. Tricuspid Atresia. In: Pediatric Cardiology. 3rd ed. Philadelphia, PA: WB Saunders; 1972.

  6. Svensson EC, Huggins GS, Lin H, et al. A syndrome of tricuspid atresia in mice with a targeted mutation of the geneencoding Fog-2. Nat Genet. Jul 2000;25(3):353-6. [Medline].

  7. Mahle WT, Wernovsky G, Bridges ND, et al. Impact of early ventricular unloading on exercise performance in preadolescentswith single ventricle Fontan physiology. J Am Coll Cardiol. Nov 1 1999;34(5):1637-43. [Medline].

  8. Choussat A, Fontan F, Besse P. Selection Criteria for the Fontan procedure. In: Anderson RH, Shinebourne EA, eds. Paediatric Cardiology. Edinburgh: Churchill Livingstone;. 1977: 559-66.

  9. Kuhne M. Ueber zwei Faelle kongenitaler Atresie des Ostium venosum dextrum. Jahresb Kinderh. 1906;63:225.

  10. Tandon R, Edwards JE. Tricuspid atresia. A re-evaluation and classification. J Thorac Cardiovasc Surg. Apr 1974;67(4):530-42. [Medline].

  11. Dick M, Rosenthal A, Bove E. The clinical profile of tricuspid atresia. In: Tricuspid Atresia, Rao PS, ed. Mt Kisco, New York;. 1992: 117.

  12. Dick M, Fyler DC, Nadas AS. Tricuspid atresia: clinical course in 101 patients. Am J Cardiol. Sep 1975;36(3):327-37. [Medline].

  13. Weber HS, Gleason MM, Myers JL, et al. The Fontan operation in infants less than 2 years of age. J Am Coll Cardiol. Mar 15 1992;19(4):828-33. [Medline].

  14. Smythe JF, Copel JA, Kleinman CS. Outcome of prenatally detected cardiac malformations. Am J Cardiol. Jun 1 1992;69(17):1471-4. [Medline].

  15. Fogel MA. Is routine cardiac catheterization necessary in the management of patientswith single ventricles across staged Fontan reconstruction? No!. Pediatr Cardiol. Mar-Apr 2005;26(2):154-8. [Medline].

  16. Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, et al. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiovasc Surg. Apr 28 2010;[Medline].

  17. Salim MA, DiSessa TG, Arheart KL, Alpert BS. Contribution of superior vena caval flow to total cardiac output in children.A Doppler echocardiographic study. Circulation. Oct 1 1995;92(7):1860-5. [Medline].

  18. Puga FJ, Chiavarelli M, Hagler DJ. Modifications of the Fontan operation applicable to patients with left atrioventricularvalve atresia or single atrioventricular valve. Circulation. Sep 1987;76(3 Pt 2):III53-60. [Medline].

  19. Jonas RA, Castaneda AR. Modified Fontan procedure: atrial baffle and systemic venous to pulmonary arteryanastomotic techniques. J Card Surg. Jun 1988;3(2):91-6. [Medline].

  20. de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J Thorac Cardiovasc Surg. Nov 1988;96(5):682-95. [Medline].

  21. Marcelletti C, Corno A, Giannico S, Marino B. Inferior vena cava-pulmonary artery extracardiac conduit. A new form of rightheart bypass. J Thorac Cardiovasc Surg. Aug 1990;100(2):228-32. [Medline].

  22. Laschinger JC, Ringel RE, Brenner JI, McLaughlin JS. Extracardiac total cavopulmonary connection. Ann Thorac Surg. Aug 1992;54(2):371-3. [Medline].

  23. Bridges ND, Mayer JE, Lock JE, et al. Effect of baffle fenestration on outcome of the modified Fontan operation. Circulation. Dec 1992;86(6):1762-9. [Medline].

  24. Lemler MS, Scott WA, Leonard SR, et al. Fenestration improves clinical outcome of the fontan procedure: a prospective,randomized study. Circulation. Jan 15 2002;105(2):207-12. [Medline].

  25. Monagle P, Cochrane A, Roberts R, Manlhiot et al. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic Acid as primary thromboprophylaxis for 2 years after the fontan procedure in children. J Am Coll Cardiol. Aug 2 2011;58(6):645-51. [Medline].

  26. Mertens L, Hagler DJ, Sauer U, et al. Protein-losing enteropathy after the Fontan operation: an international multicenterstudy. PLE study group. J Thorac Cardiovasc Surg. May 1998;115(5):1063-73. [Medline].

  27. Minamisawa S, Nakazawa M, Momma K, et al. Effect of aerobic training on exercise performance in patients after the Fontanoperation. Am J Cardiol. Sep 15 2001;88(6):695-8. [Medline].

  28. Coon PD, Rychik J, Novello RT, et al. Thrombus formation after the Fontan operation. Ann Thorac Surg. Jun 2001;71(6):1990-4. [Medline].

  29. Ravn HB, Hjortdal VE, Stenbog EV, et al. Increased platelet reactivity and significant changes in coagulation markersafter cavopulmonary connection. Heart. Jan 2001;85(1):61-5. [Medline].

  30. Cohen MI, Bush DM, Ferry RJ, et al. Somatic growth failure after the Fontan operation. Cardiol Young. Sep 2000;10(5):447-57. [Medline].

  31. Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M, Breymann T. Somatic development long after the Fontan operation: factors influencing catch-up growth. J Thorac Cardiovasc Surg. Nov 2007;134(5):1199-206. [Medline].

  32. Mahle WT, Clancy RR, Moss EM, et al. Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescentchildren with hypoplastic left heart syndrome. Pediatrics. May 2000;105(5):1082-9. [Medline].

  33. Wernovsky G, Stiles KM, Gauvreau K, et al. Cognitive development after the Fontan operation. Circulation. Aug 22 2000;102(8):883-9. [Medline].

  34. Goldberg CS, Schwartz EM, Brunberg JA, et al. Neurodevelopmental outcome of patients after the fontan operation: A comparison between children with hypoplastic left heart syndrome and other functional single ventricle lesions. J Pediatr. Nov 2000;137(5):646-52. [Medline].

  35. Ovroutski S, Dahnert I, Alexi-Meskishvili V, et al. Preliminary analysis of arrhythmias after the Fontan operation with extracardiacconduit compared with intra-atrial lateral tunnel. Thorac Cardiovasc Surg. Dec 2001;49(6):334-7. [Medline].

  36. McElhinney DB, Marx GR, Marshall AC, Mayer JE, Del Nido PJ. Cavopulmonary pathway modification in patients with heterotaxy and newly diagnosed or persistent pulmonary arteriovenous malformations after a modified Fontan operation. J Thorac Cardiovasc Surg. Jun 2011;141(6):1362-1370.e1. [Medline].

  37. Gaynor JW, Bridges ND, Cohen MI, et al. Predictors of outcome after the Fontan operation: is hypoplastic left heartsyndrome still a risk factor?. J Thorac Cardiovasc Surg. Feb 2002;123(2):237-45. [Medline].

  38. Earing MG, Cetta F, Driscoll DJ, et al. Long-term results of the Fontan operation for double-inlet left ventricle. Am J Cardiol. Jul 15 2005;96(2):291-8. [Medline].

  39. Wallace MC, Jaggers J, Li JS, et al. Center variation in patient age and weight at fontan operation and impact on postoperative outcomes. Ann Thorac Surg. May 2011;91(5):1445-52. [Medline].

  40. Yeh T, Williams WG, McCrindle BW, et al. Equivalent survival following cavopulmonary shunt: with or without the Fontanprocedure. Eur J Cardiothorac Surg. Aug 1999;16(2):111-6. [Medline].

  41. Alexiou C, Delany DJ, Keeton BR, Monro JL. Double-barreled conduit for right atrioventricular connection in tricuspid atresia: a new technique. J Thorac Cardiovasc Surg. Oct 2000;120(4):820-2. [Medline].

  42. Anderson RH, Wilkinson JL, Gerlis LM, et al. Atresia of the right atrioventricular orifice. Br Heart J. Apr 1977;39(4):414-28. [Medline].

  43. Annecchino FP, Fontan F, Chauve A, Quaegebeur J. Palliative reconstruction of the right ventricular outflow tract in tricuspid atresia: a report of 5 patients. Ann Thorac Surg. Apr 1980;29(4):317-21. [Medline].

  44. Behrendt DM, Rosenthal A. Cardiovascular status after repair by Fontan procedure. Ann Thorac Surg. Apr 1980;29(4):322-30. [Medline].

  45. Chopra PS, Rao PS. Corrective surgery for tricuspid atresia: which modification of Fontan-Kreutzer procedure should be used? A review. Am Heart J. Mar 1992;123(3):758-67. [Medline].

  46. Cohen MI, Bridges ND, Gaynor JW, et al. Modifications to the cavopulmonary anastomosis do not eliminate early sinusnode dysfunction. J Thorac Cardiovasc Surg. Nov 2000;120(5):891-900. [Medline].

  47. Dore A, Somerville J. Right atrioventricular extracardiac conduit as a fontan modification: late results. Ann Thorac Surg. Jan 2000;69(1):181-5. [Medline].

  48. Durongpisitkul K, Porter CJ, Cetta F, et al. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation. Sep 15 1998;98(11):1099-107. [Medline].

  49. Ensley AE, Lynch P, Chatzimavroudis GP, et al. Toward designing the optimal total cavopulmonary connection: an in vitro study. Ann Thorac Surg. Oct 1999;68(4):1384-90. [Medline].

  50. Facchini M, Guldenschuh I, Turina J, et al. Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia. J Cardiovasc Surg (Torino). Aug 2000;41(4):567-70. [Medline].

  51. Franklin RC, Spiegelhalter DJ, Sullivan ID, et al. Tricuspid atresia presenting in infancy. Survival and suitability for the Fontan operation. Circulation. Feb 1993;87(2):427-39. [Medline].

  52. Freedom RM, Hamilton R, Yoo SJ, et al. The Fontan procedure: analysis of cohorts and late complications. Cardiol Young. Oct 2000;10(4):307-31. [Medline].

  53. Gale AW, Danielson GK, McGoon DC. Fontan procedure for tricuspid atresia. Circulation. Jul 1980;62(1):91-6. [Medline].

  54. Haas GS, Hess H, Black M, et al. Extracardiac conduit fontan procedure: early and intermediate results. Eur J Cardiothorac Surg. Jun 2000;17(6):648-54. [Medline].

  55. Hager A, Zrenner B, Brodherr-Heberlein S, et al. Congenital and surgically acquired Wolff-Parkinson-White syndrome in patientswith tricuspid atresia. J Thorac Cardiovasc Surg. Jul 2005;130(1):48-53. [Medline].

  56. Hess J. Long-term problems after cavopulmonary anastomosis: diagnosis and management. Thorac Cardiovasc Surg. Apr 2001;49(2):98-100. [Medline].

  57. Jaquiss RD, Ghanayem NS, Hoffman GM, et al. Early cavopulmonary anastomosis in very young infants after the Norwood procedure:impact on oxygenation, resource utilization, and mortality. J Thorac Cardiovasc Surg. Apr 2004;127(4):982-9. [Medline].

  58. Karamlou T, Ashburn DA, Caldarone CA, et al. Matching procedure to morphology improves outcomes in neonates with tricuspidatresia. J Thorac Cardiovasc Surg. Dec 2005;130(6):1503-10. [Medline].

  59. Kirklin JK, Blackstone EH, Kirklin JW, et al. The Fontan operation. Ventricular hypertrophy, age, and date of operation as risk factors. J Thorac Cardiovasc Surg. Dec 1986;92(6):1049-64. [Medline].

  60. Lee CN, Schaff HV, Danielson GK, et al. Comparison of atriopulmonary versus atrioventricular connections for modified Fontan/Kreutzer repair of tricuspid valve atresia. J Thorac Cardiovasc Surg. Dec 1986;92(6):1038-43. [Medline].

  61. Mair DD, Puga FJ, Danielson GK. The Fontan procedure for tricuspid atresia: early and late results of a 25-yearexperience with 216 patients. J Am Coll Cardiol. Mar 1 2001;37(3):933-9. [Medline].

  62. Park SC, Neches WH, Mullins CE, et al. Blade atrial septostomy: collaborative study. Circulation. Aug 1982;66(2):258-66. [Medline].

  63. Sanders SP, Wright GB, Keane JF, et al. Clinical and hemodynamic results of the Fontan operation for tricuspid atresia. Am J Cardiol. May 1982;49(7):1733-40. [Medline].

  64. Sano S, Ishino K, Kawada M, et al. Staged biventricular repair of pulmonary atresia or stenosis with intact ventricular septum. Ann Thorac Surg. Nov 2000;70(5):1501-6. [Medline].

  65. Stefanelli G, Kirklin JW, Naftel DC, et al. Early and intermediate-term (10-year) results of surgery for univentricular atrioventricular connection ("single ventricle"). Am J Cardiol. Oct 1 1984;54(7):811-21. [Medline].

  66. Takeda M, Shimada M, Sekiguchi A, Ishizawa A. Long-term results of the fenestrated Fontan operation. Progress of patients with patent fenestrations. Jpn J Thorac Cardiovasc Surg. Sep 1999;47(9):432-9. [Medline].

  67. van den Bosch AE, Roos-Hesselink JW, Van Domburg R, et al. Long-term outcome and quality of life in adult patients after the Fontan operation. Am J Cardiol. May 1 2004;93(9):1141-5. [Medline].

  68. van Doorn CA, de Leval MR. The Fontan operation in clinical practice: indications and controversies. Nat Clin Pract Cardiovasc Med. Mar 2005;2(3):116-7. [Medline].

  69. van Son JA, Mohr FW, Hambsch J, et al. Conversion of atriopulmonary or lateral atrial tunnel cavopulmonary anastomosis to extracardiac conduit Fontan modification. Eur J Cardiothorac Surg. Feb 1999;15(2):150-7; discussion 157-8. [Medline].

  70. Weinberg PM. Anatomy of tricuspid atresia and its relevance to current forms of surgical therapy. Ann Thorac Surg. Apr 1980;29(4):306-11. [Medline].

  71. Wong ML, Sim EK, Goh JJ, et al. Bidirectional cavopulmonary anastomosis. Ann Acad Med Singapore. Mar 1999;28(2):237-40. [Medline].

Previous
Next
 
Polytetrafluoroethylene (PTFE, Gore-Tex; W. L. Gore & Associates, Newark, DE) patch used to fashion the lateral tunnel in the Fontan operation.
Bidirectional Glenn procedure. SVC = superior vena cava.
Completion of the bidirectional Glenn operation. SVC = superior vena cava.
Hemi-Fontan procedure.
Lateral-tunnel Fontan procedure.
Extracardiac Fontan operation.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.